Titre :
|
Getting insurance after genetic screening on familial hypercholesterolaemia ; the need to educate both insurers and the public to increase adherence to national guidelines in the Netherlands. (2002)
|
Auteurs :
|
P.J. MARANG-VAN DE MHEEN ;
M.E.A. STOUTHARD ;
M.C. VAN MAARLE ;
Department of Social Medicine. Academic Medical Centre. Amsterdam. NLD
|
Type de document :
|
Article
|
Dans :
|
Journal of epidemiology and community health (vol. 56, n° 2, 2002)
|
Pagination :
|
145-147
|
Langues:
|
Anglais
|
Mots-clés :
|
Hypercholestérolémie
;
Maladie héréditaire
;
Dépistage
;
Assurance maladie
;
Protection sociale
;
Recommandation
;
Projet loi
;
Europe
;
Homme
;
Lipide
;
Métabolisme [pathologie]
;
Hyperlipoprotéinémie
;
Pays Bas
|
Résumé :
|
[BDSP. Notice produite par INIST-CNRS 8aPR0xZF. Diffusion soumise à autorisation]. Heterozygous familial hypercholesterolaemia (FH) is a common autosomal dominant inherited metabolic disease with a prevalence of 1 in 500 in most Western countries. 1-3 People with FH experience an increased risk for coronary artery disease (CAD) and excess mortality especially at a young age. 4 5 Until recently the diagnosis of FH was based on clinical signs and symptoms alone. These included increased cholesterol concentrations, in particular of LDL-cholesterol, in combination with the presence of tendon xanthoma, corneal arcus, xanthelasmata and a history of early CAD. Frequently FH was diagnosed after a first cardiac event.
|